Tick-borne encephalitis vaccine

Tick-borne encephalitis vaccine

Tick-borne encephalitis vaccine is a vaccine used against tick-borne encephalitis (TBE).

The vaccine is highly immunogenic, with seroconversion rates of over 87%.[1]

The first vaccine against TBE was prepared in 1941 in the brains of mice. Some 20 years later TBE vaccines derived from cell cultures (chicken embryo fibroblast cells) were developed and used for active immunization in humans in the former Soviet Union. Later, a purified, inactivated virus vaccine was developed which proved to be more immunogenic than previous TBE vaccines.

The efficacy of these vaccines has been well documented. They have also been shown to protect mice from a lethal challenge with several TBE-virus isolates obtained over a period of more than 30 years from all over Europe and the Asian part of the former Soviet Union. In addition, it has been demonstrated that antibodies induced by vaccination of human volunteers neutralized all tested isolates.


External links

  • http://www.who.int/biologicals/areas/vaccines/tick_encephalitis/en/
  • The Encephalitis Society - A Global resource on Encephalitis